- Home
- ADAP vs PNI Comparison
ADAP vs PNI Comparison
Compare ADAP & PNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- PNI
- Stock Information
- Founded
- ADAP 2008
- PNI 2002
- Country
- ADAP United Kingdom
- PNI United States
- Employees
- ADAP 506
- PNI N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- PNI Trusts Except Educational Religious and Charitable
- Sector
- ADAP Health Care
- PNI Finance
- Exchange
- ADAP Nasdaq
- PNI Nasdaq
- Market Cap
- ADAP 75.5M
- PNI 82.7M
- IPO Year
- ADAP 2015
- PNI N/A
- Fundamental
- Price
- ADAP $0.29
- PNI $6.87
- Analyst Decision
- ADAP Strong Buy
- PNI
- Analyst Count
- ADAP 5
- PNI 0
- Target Price
- ADAP $1.83
- PNI N/A
- AVG Volume (30 Days)
- ADAP 777.8K
- PNI 26.4K
- Earning Date
- ADAP 05-13-2025
- PNI 01-01-0001
- Dividend Yield
- ADAP N/A
- PNI 4.76%
- EPS Growth
- ADAP N/A
- PNI N/A
- EPS
- ADAP N/A
- PNI N/A
- Revenue
- ADAP $178,032,000.00
- PNI N/A
- Revenue This Year
- ADAP N/A
- PNI N/A
- Revenue Next Year
- ADAP $69.81
- PNI N/A
- P/E Ratio
- ADAP N/A
- PNI N/A
- Revenue Growth
- ADAP 195.34
- PNI N/A
- 52 Week Low
- ADAP $0.20
- PNI $6.03
- 52 Week High
- ADAP $1.48
- PNI $7.89
- Technical
- Relative Strength Index (RSI)
- ADAP 51.38
- PNI 52.88
- Support Level
- ADAP $0.30
- PNI $6.70
- Resistance Level
- ADAP $0.32
- PNI $6.92
- Average True Range (ATR)
- ADAP 0.02
- PNI 0.09
- MACD
- ADAP 0.01
- PNI 0.04
- Stochastic Oscillator
- ADAP 67.44
- PNI 86.11
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.